Publications by authors named "Ana Filipa Fonseca"
Background And Aims: Elevated lipoprotein(a) [Lp(a)] is a genetic driver for atherosclerotic cardiovascular disease (ASCVD). We aimed to provide novel insights into the associated risk of elevated versus normal Lp(a) levels on major adverse cardiovascular events (MACE) in an incident ASCVD cohort.
Methods: This was an observational cohort study of incident ASCVD patients.
Article Synopsis
- Elevated lipoprotein(a) [Lp(a)] is a significant genetic risk factor for atherosclerotic cardiovascular disease (ASCVD), increasing the risk by 2-4 times, which is particularly concerning in patients undergoing secondary prevention.
- A systematic literature review was conducted to analyze studies from 2010 to 2022 that assessed the clinical impact of elevated Lp(a) levels, resulting in 61 studies, with 26 specifically addressing the burden of elevated levels on health outcomes.
- Key findings indicated that elevated Lp(a) levels are linked to a higher risk of major cardiovascular events, myocardial infarction, and cognitive impairments, showcasing a negative effect on patients' health-related quality of life, although meta-analysis was hindered by
Objectives: To examine healthcare resource use (HRU) and costs among heart failure (HF) patients using population data from Sweden.
Design: Retrospective, non-interventional cohort study.
Setting: Two cohorts were identified from linked national health registers (cohort 1, 2005-2014) and electronic medical records (cohort 2, 2010-2012; primary/secondary care patients from Uppsala and Västerbotten).
Purpose: To characterize symptoms, clinical burden, and health-related quality of life (HRQoL) among women and men with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ≤60% in Europe.
Patients And Methods: A real-world cross-sectional study was conducted in France, Germany, Italy, Spain, and United Kingdom from June to November 2019. Patient record forms were completed by 257 cardiologists and 158 general practitioners for consecutive patients with HF.
Purpose: To assess the burden among caregivers of patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≤60%. The burden by New York Heart Association (NYHA) functional class was also characterized.
Patients And Methods: A cross-sectional study was conducted in France, Germany, Italy, Spain, and UK from June to November 2019.
Aims: Heart failure (HF) is a leading cause of hospitalization and is associated with high morbidity and mortality. We examined the impact of recurrent HF hospitalizations (HFHs) on cardiovascular (CV) mortality among patients with HF in Sweden.
Methods And Results: Adults with incident HF were identified from linked national health registers and electronic medical records from 01 January 2005 to 31 December 2013 for Uppsala and until 31 December 2014 for Västerbotten.
Aims: The aim of this paper was to analyse heart failure (HF) signs and symptoms, hospital referrals, and prescription patterns in patients receiving sacubitril/valsartan (sac/val) in primary care and cardiology settings in Germany.
Methods And Results: A retrospective cohort study of electronic medical records identified 1263 adults (aged ≥18 years) in the German IMS® Disease Analyzer database who were prescribed sac/val during 2016 and had at least 6 months of data following sac/val initiation. Clinical characteristics were collected during the 12 months before the first recorded sac/val prescription (index date) and 6 months post-index.